Heart Test Laboratories, Inc. Files S-1 Registration Statement

TL;DR

<b>Heart Test Laboratories, Inc. has filed an S-1 registration statement for the proposed sale of securities.</b>

AI Summary

Heart Test Laboratories, Inc. (HSCSW) filed a IPO Registration (S-1) with the SEC on March 5, 2024. Heart Test Laboratories, Inc. filed an S-1 registration statement with the SEC on March 5, 2024. The company is incorporated in Texas and has its principal executive offices in Southlake, Texas. The filing is for a registration statement under the Securities Act of 1933. The SIC code for the company is 3842 (Orthopedic, Prosthetic & Surgical Appliances & Supplies). The filing indicates the proposed sale of securities will commence as soon as practicable after the effective date.

Why It Matters

For investors and stakeholders tracking Heart Test Laboratories, Inc., this filing contains several important signals. This S-1 filing is a crucial step for Heart Test Laboratories, Inc. as it signals their intent to offer securities to the public, potentially raising capital for growth or operations. The filing provides the initial public disclosure of the company's business, financial condition, and the terms of the securities being offered, allowing investors to assess the opportunity.

Risk Assessment

Risk Level: low — Heart Test Laboratories, Inc. shows low risk based on this filing. The filing is an S-1 registration statement, which is a preliminary step for a public offering and does not contain detailed financial performance data or operational results that would indicate immediate risk.

Analyst Insight

Monitor future filings for the prospectus and details on the securities offering, including pricing and the use of proceeds.

Key Numbers

• S-1 — Form Type (Registration Statement)
• 2024-03-05 — Filing Date (Date of filing with SEC)
• 333-277675 — SEC File Number (Registration number)
• 0430 — Fiscal Year End (Company's fiscal year end)
• 261344466 — IRS Number (Employer Identification Number)
• 3842 — SIC Code (Standard Industrial Classification)

Key Players & Entities

• Heart Test Laboratories, Inc. (company) — Filer name
• SEC (regulator) — Securities and Exchange Commission
• 20240305 (date) — Filing date
• 333-277675 (registration_number) — SEC File Number
• 0001213900-24-020156 (accession_number) — Accession Number
• Texas (location) — State of incorporation
• Southlake, Texas (location) — Business address
• Danielle Watson (person) — Agent for service

FAQ

Industry Context

The company operates within the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry, as indicated by its SIC code.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public.

What Investors Should Do

1. Review the full S-1 filing for detailed business descriptions and risk factors.
2. Track subsequent SEC filings for prospectus details and offering terms.
3. Analyze the company's financial health and market position once more information is available.

Key Dates

• 2024-03-05: Filing of S-1 Registration Statement — Indicates intent to offer securities to the public.

Year-Over-Year Comparison

This is the initial S-1 filing, so there is no prior filing of this type to compare against for this specific offering.

Key Financial Figures

• $0.001 — &#x201c;Company&#x201d;) common stock, $0.001 par value per share (the &#x201c;Common
• $0.1164 — Stock on the Nasdaq Capital Market was $0.1164 per share&#x00a0;and the closing price
• $0.0 — ng price of&#x00a0;our IPO Warrants was $0.0 85 &#x00a0;per warrant. We are an &#x

Filing Documents

• ea0200010-01.htm (S-1) — 1111KB
• ea0200010ex5-1_hearttes.htm (EX-5.1) — 15KB
• ea0200010ex23-1_hearttes.htm (EX-23.1) — 3KB
• ea0200010ex-fee_hearttes.htm (EX-FILING FEES) — 23KB
• theart_logo.jpg (GRAPHIC) — 47KB
• timage_001.jpg (GRAPHIC) — 63KB
• ex5-1_001.jpg (GRAPHIC) — 10KB
• 0001213900-24-020156.txt (&nbsp;) — 1318KB

RISK FACTORS

RISK FACTORS &#x00a0; 20

USE OF PROCEEDS

USE OF PROCEEDS &#x00a0; 23 MARKET FOR COMMON STOCK AND DIVIDEND POLICY &#x00a0; 24 SELLING STOCKHOLDERS TRANSACTIONS &#x00a0; 25 SELLING STOCKHOLDERS &#x00a0; 31 PLAN OF DISTRIBUTION &#x00a0; 34 DESCRIPTION OF OUR SECURITIES &#x00a0; 37 LEGAL MATTERS &#x00a0; 47 EXPERTS &#x00a0; 47 WHERE YOU CAN FIND ADDITIONAL INFORMATION &#x00a0; 47 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT&#x00a0;LIABILITIES &#x00a0; 48 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE &#x00a0; 48 GLOSSARY OF TERMS &#x00a0; 49 i Table of Contents ABOUT THIS PROSPECTUS The Registration Statement on Form&#x00a0;S -1 of which this prospectus forms a part and that we have filed with the U.S.&#x00a0;Securities and Exchange Commission (the &#x201c;SEC&#x201d;), includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus and the related exhibits filed with the SEC, together with the additional information described under the heading &#x201c;Where You Can Find Additional Information.&#x201d; You should rely only on the information we have provided in this prospectus, any applicable prospectus supplement and any related free writing prospectus. We have not authorized anyone to provide you with information different from that contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. You must not rely on any unauthorized information or representation. This prospectus is an offer to sell only the Shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus, any applicable prospectus supplement or any

View Full Filing

View this S-1 filing on SEC EDGAR